Doctors Note Logo

Published on: 9/26/2026

Can Xarelto damage your liver, and what is monitored?

Xarelto (rivaroxaban) can, in rare cases, cause drug-induced liver injury, with warning signs such as yellowing of the skin or eyes, dark urine, unusual fatigue, nausea, or pain in the upper right abdomen, most often within the first few weeks to months of starting treatment. Because of this, clinicians generally check liver enzymes (ALT, AST) and bilirubin before starting and periodically afterward, along with kidney function, hemoglobin, and signs of bleeding, since impaired liver or kidney clearance raises drug levels and bleeding risk. Several factors change how closely you need monitoring, including existing liver disease, alcohol use, and other medications, so review the complete details below before drawing conclusions about your own situation.

If you have noticed jaundice, fatigue, dark urine, abdominal discomfort, or unexpected bruising while taking a blood thinner, those symptoms deserve a prompt, structured evaluation rather than guesswork, because some causes are harmless and others need urgent care. Take a free, instant, online symptom check to see which possibilities fit your pattern and get clear guidance on what to do next.

Last reviewed for medical accuracy: 09/26/2026

answer background

Explanation

Can Xarelto Damage Your Liver? What Is Monitored?

Xarelto (rivaroxaban) is an oral anticoagulant used to prevent and treat blood clots. Because it’s processed by the liver, many people ask: will Xarelto have an effect on my liver or cause liver damage? In most cases, serious liver injury is rare. However, monitoring and awareness help keep you safe. Below we explain what the research shows, how your body handles Xarelto, and what tests and signs your doctor will watch.


How Xarelto Interacts with the Liver

  • Xarelto is broken down (metabolized) partly in the liver by enzymes called CYP3A4 and CYP2J2.
  • Most of the dose is excreted through urine and feces; only a small portion stays in circulation long enough to affect liver cells.
  • In clinical trials and post-marketing reports, a small number of patients experienced mild to moderate elevations in liver enzymes (markers of liver stress).

Key points from prescribing data:

  • Transient increases in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of normal occurred in about 1–2% of patients.
  • Severe liver injury or acute liver failure linked directly to Xarelto is extremely rare.
  • Patients with severe hepatic impairment (Child-Pugh Class C) should not take Xarelto. Those with moderate impairment (Child-Pugh Class B) require caution.

Will Xarelto Have an Effect on My Liver or Cause Liver Damage?

Although serious cases are uncommon, you may wonder whether Xarelto could harm your liver over time. Here’s what studies and real-world experience show:

  • Most patients do not develop clinically significant liver damage.
  • Mild bumps in liver enzymes often resolve on their own, without stopping Xarelto.
  • No clear pattern of chronic liver disease has emerged in people taking Xarelto for months or years.
  • The risk of bleeding complications generally outweighs any minimal risk of liver injury.

Take-home message: for the vast majority of users, Xarelto’s benefits in preventing dangerous clots far exceed the low chance of liver enzyme changes. Still, it’s smart to stay informed and follow your doctor’s recommendations.


Who’s at Higher Risk?

Certain factors can make your liver more vulnerable while taking Xarelto:

  • Pre-existing liver disease (hepatitis, cirrhosis, fatty liver)
  • Chronic heavy alcohol use
  • Use of other hepatotoxic (liver-damaging) drugs or supplements
  • Genetic variations affecting liver enzymes
  • Elderly age, which can slow drug clearance

If any of these apply, your doctor may monitor you more closely or choose a different blood thinner.


What Liver Function Tests (LFTs) Are Monitored?

To catch any early signs of stress or damage, physicians often order routine labs:

  • ALT (Alanine Aminotransferase) – indicates damage to liver cells
  • AST (Aspartate Aminotransferase) – another marker of liver cell injury
  • Alkaline Phosphatase (ALP) – elevated in bile duct obstruction or certain liver diseases
  • Bilirubin – high levels can signal impaired liver clearance
  • Albumin and Total Protein – low albumin may reflect chronic liver dysfunction

Monitoring schedule:

  1. Baseline LFTs before starting Xarelto
  2. Re‐check at 1–3 months, then annually if stable
  3. More frequent checks if you develop symptoms or have other liver risks

Signs and Symptoms to Watch For

Besides lab tests, be alert for any symptoms that could suggest liver strain:

  • Unexplained fatigue or weakness
  • Yellowing of the skin or eyes (jaundice)
  • Dark urine or pale stools
  • Persistent nausea, vomiting, or abdominal pain
  • Unusual bruising or bleeding not related to anticoagulation

If you notice any of these signs, reach out to your healthcare provider right away.


Balancing Benefits and Risks

While the idea of liver damage can sound alarming, remember:

  • The main goal of Xarelto is to prevent strokes, deep vein thrombosis, and pulmonary embolism—conditions that can be life-threatening.
  • Mild, transient liver enzyme elevations do not usually require stopping the medicine.
  • Your doctor will weigh your individual risk factors (age, kidney function, other meds) to find the right dose and monitoring plan.

Staying proactive with appointments and lab work helps you and your doctor keep risks low.


What Else Is Monitored on Xarelto?

Beyond liver tests, some additional checks include:

  • Kidney function (creatinine, eGFR): Xarelto is partly cleared by the kidneys.
  • Complete blood count: To watch for bleeding or low platelets.
  • Signs of bleeding: Unusual bruising, nosebleeds, blood in urine or stool.

These assessments, combined with liver tests, create a full picture of how you’re tolerating treatment.


When to Talk to Your Doctor

If you’re concerned about liver health or experience any worrying symptoms:

  • Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help clarify what you’re feeling.
  • Bring your lab results and a list of any supplements or over-the-counter medicines you take.
  • Ask specifically about dosing adjustments if your liver tests rise moderately.
  • Discuss alternative anticoagulants if you have moderate to severe liver disease.

Your healthcare team can tailor an approach that balances clot prevention with liver safety.


Speak to a doctor if you experience any serious or life-threatening symptoms—such as severe abdominal pain, sudden jaundice, or uncontrollable bleeding—while taking Xarelto. Always rely on your physician’s guidance for personalized advice and treatment.

(References)

  • * Samama MM, Gerotziafas G. [New antitoagulants]. Ann Pharm Fr. 2007 Mar;65(2):85-94. doi: 10.1016/s0003-4509(07)90021-8. PMID: 17404541.

  • * Van Cott EM, Khor B, Zehnder JL. Factor V Leiden. Am J Hematol. 2016 Jan;91(1):46-9. doi: 10.1002/ajh.24222. Epub 2015 Nov 17. PMID: 26492443.

  • * Rivaroxaban: liver injury. Prescrire Int. 2015 Nov;24(165):268. PMID: 26688900.

  • * Christopoulou EC, Filippatos TD, Elisaf MS. Non-hemorrhage-related adverse effects of rivaroxaban. Arch Med Sci Atheroscler Dis. 2017;2:e108-e112. doi: 10.5114/amsad.2017.72533. Epub 2017 Dec 31. PMID: 29379891; PMCID: PMC5777473.

  • * Verheyen E, Kileci JA, Mathew JP. Single-Dose Rivaroxaban-Induced Acute Liver Injury. Am J Ther. 2019 Jul/Aug;26(4):e538-e540. doi: 10.1097/MJT.0000000000000799. PMID: 29889676.

  • * Rivaroxaban. 2012. PMID: 31643347.

  • * Antithrombotic Agents. 2012. PMID: 31643990.

  • * Abrignani MG, Gatta L, Gabrielli D, Milazzo G, De Francesco V, De Luca L, Francese M, Imazio M, Riccio E, Rossini R, Scotto di Uccio F, Soncini M, Zullo A, Colivicchi F, Di Lenarda A, Gulizia MM, Monica F. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021 Mar;85:1-13. doi: 10.1016/j.ejim.2020.11.014. Epub 2020 Dec 2. PMID: 33279389.

  • * Juneja D, Nasa P, Jain R. Liver injury from direct oral anticoagulants. World J Hepatol. 2023 Jun 27;15(6):841-849. doi: 10.4254/wjh.v15.i6.841. PMID: 37397936; PMCID: PMC10308284.

  • * Puente Á, Turón F, Martínez J, Fortea JI, Guerra MH, Alvarado E, Pons M, Magaz M, Llop E, Alvarez-Navascués C, Navarrete AA, Berenguer M, Masnou H, Bañares R, Casado M, Ampuero J, Rios J, Saavedra C, Blasi A, Lisman T, Figuero CR, Huelin P, Tellez L, Arráez DM, Rodriguez M, Aguilera V, Arias Loste MT, Baiges A, Hernandez-Gea V, Perelló C, Calleja JL, Genescà J, Villanueva C, Gonzalez-Alayón C, Albillos A, Crespo J, García-Pagán JC. Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study. J Hepatol. 2025 Nov;83(5):1069-1076. doi: 10.1016/j.jhep.2025.06.035. Epub 2025 Jul 19. PMID: 40691992.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.